Guidelines and recommendations for MRI in breast cancer follow-up: A review

被引:9
|
作者
van Bodegraven, Eduard A. [1 ]
van Raaij, Jeroen C. [1 ]
Van Goethem, Mireille [1 ]
Tjalma, Wiebren A. A. [1 ]
机构
[1] Univ Antwerp, Antwerp Univ Hosp, Dept Obstet & Gynaecol, Gynaecol Oncol Unit,Multidisciplinary Breast Clin, B-2650 Antwerp, Belgium
关键词
Breast cancer; Imaging; Follow-up; Recurrence; Guidelines; MRI; PERSONAL HISTORY; RISK-FACTOR; WOMEN; RECURRENCE; SOCIETY;
D O I
10.1016/j.ejogrb.2017.09.009
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: Present article will perform a review regarding the current-recommendations of Magnetic resonance imaging (MRI) in routine follow-up after successfully treated breast cancer by surgery, radiation and/or systemic therapy. Methods: For this review, a literature review search was done with the MeSH-terms: Magnetic Resonance Imaging, breast neoplasm, post-operative period and follow-up, according to PRISMA. The literature published between 2006 and 2016 in MedBase, PubMed and Embase was consulted. Results: The 10 articles and 8 guidelines were analysed for their recommendations regarding MRI use in routine follow-up for breast cancer. One article concluded that MRI could influence further policy, all others did not find superiority of MRI over mammography or were inconclusive. One guideline recommended annual MRI for patients with a positive personal history (PPH) for breast cancer without further risk factors, one guideline offered no MRI to these patients and all other guidelines were inconclusive. Conclusion: There is insufficient evidence regarding superiority of MRI versus mammography in routine follow-up for patients with a PPH of breast cancer. MRI does not improve survival in all patients and should therefore not be offered to patients in follow-up without increased risk for recurrences. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:5 / 11
页数:7
相关论文
共 50 条
  • [21] Are American follow-up recommendations in endocrinology actionable? A systematic review of clinical practice guidelines
    Barrera, Francisco J.
    Raygoza-Cortez, Karina
    Garcia-Leal, Mariana
    Brito, Juan P.
    Ospina, Naykky M. Singh
    Rodriguez-Gutierrez, Rene
    ENDOCRINE, 2021, 72 (02) : 375 - 384
  • [22] Are American follow-up recommendations in endocrinology actionable? A systematic review of clinical practice guidelines
    Francisco J. Barrera
    Karina Raygoza-Cortez
    Mariana García-Leal
    Juan P. Brito
    Naykky M. Singh Ospina
    René Rodríguez-Gutiérrez
    Endocrine, 2021, 72 : 375 - 384
  • [23] MRI in routine breast cancer follow-up: correlation with clinical outcome
    Coulthard, A
    Beveridge, CJ
    Potterton, AJ
    CLINICAL RADIOLOGY, 1999, 54 (07) : 459 - 461
  • [24] Preoperative breast MRI and follow-up recommendations for the contralateral breast influence the rate of contralateral prophylactic mastectomy
    Xia, C.
    Button, A. M.
    Smith, B. J.
    Grobe, C. C.
    Schroeder, M. C.
    Sugg, S.
    Weigel, R. J.
    Thomas, A.
    CANCER RESEARCH, 2013, 73
  • [25] Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
    Kataja, V.
    Castiglione, M.
    ANNALS OF ONCOLOGY, 2009, 20 : 10 - 14
  • [26] Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
    Pestalozzi, B.
    ANNALS OF ONCOLOGY, 2007, 18 : 5 - 8
  • [27] Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
    Pestalozzil, B.
    Castiglione, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 7 - 10
  • [29] Recommendations for follow-up of colorectal cancer survivors
    Vera, R.
    Aparicio, J.
    Carballo, F.
    Esteva, M.
    Gonzalez-Flores, E.
    Santianes, J.
    Santolaya, F.
    Fernandez-Cebrian, J. M.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (10): : 1302 - 1311
  • [30] Recommendations for follow-up of colorectal cancer survivors
    R. Vera
    J. Aparicio
    F. Carballo
    M. Esteva
    E. González-Flores
    J. Santianes
    F. Santolaya
    J. M. Fernández-Cebrián
    Clinical and Translational Oncology, 2019, 21 : 1302 - 1311